GLP1R and cardiovascular disorder: According to a recent metanalysis including trials with available GLP1 RA and SGLT2i specimens, it is claimed that SGLT2i and GLP1-RA demonstrate a comparable reduction in MACE among patients with documented cardiovascular disease.